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Skeletal muscle is recognized as vital to physical movement, posture, and breathing. In a less known but
critically important role, muscle inﬂuences energy and protein metabolism throughout the body. Muscle
is a primary site for glucose uptake and storage, and it is also a reservoir of amino acids stored as protein.
Amino acids are released when supplies are needed elsewhere in the body. These conditions occur with
acute and chronic diseases, which decrease dietary intake while increasing metabolic needs. Such
metabolic shifts lead to the muscle loss associated with sarcopenia and cachexia, resulting in a variety of
adverse health and economic consequences. With loss of skeletal muscle, protein and energy availability
is lowered throughout the body. Muscle loss is associated with delayed recovery from illness, slowed
wound healing, reduced resting metabolic rate, physical disability, poorer quality of life, and higher
health care costs. These adverse effects can be combatted with exercise and nutrition. Studies suggest
dietary protein and leucine or its metabolite b-hydroxy b-methylbutyrate (HMB) can improve muscle
function, in turn improving functional performance. Considerable evidence shows that use of high-
protein oral nutritional supplements (ONS) can help maintain and rebuild muscle mass and strength.
We review muscle structure, function, and role in energy and protein balance. We discuss how disease-
and age-related malnutrition hamper muscle accretion, ultimately causing whole-body deterioration.
Finally, we describe how specialized nutrition and exercise can restore muscle mass, strength, and
function, and ultimately reverse the negative health and economic outcomes associated with muscle
loss.
 2016 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Skeletal muscle is integral to physical movement, posture, and vital
actions, such as chewing, swallowing, and breathing.1,2 Skeletal
muscle also serves as a regulator of interorgan crosstalk for energy and
protein metabolism throughout the body, a less recognized but criti-
cally important role. As such, skeletal muscle is a key site for glucose
uptake and storage.3 Skeletal muscle is likewise a reservoir of amino
acids that can support protein synthesis or energy production else-
where in the body when other sources are depleted.4
This review of muscle metabolism describes how amino acids
stored as protein in muscle can be broken down through proteolysistt Nutrition.
, Departament de Bioquimica
de Barcelona, Diagonal 643,
and Long-Term Care Medicine. Thfor ultimate use in energy production. Such breakdown occurs when
energy demands are high (as with stress-induced hypermetabolism),
or when supplies are low (as in severe starvation or longer-term
protein energy malnutrition). Both of these states can be hallmarks
of many diseases, either directly as a result of disease-related dysre-
gulation of metabolism (such as in the extreme case of cancer-
cachexia) or, more subtly, as a result of the general illness-associated
loss of appetite. Muscle is therefore crucially important during
illness, both for its role in balancing the metabolic needs of other or-
gans and for its reserves of protein for use in energy production. Yet,
during illness, the maintenance of muscle mass through exercise and
nutrition are often overlooked or difﬁcult to address, and muscle at-
rophy develops. Even more subtle is aging-related muscle loss, which
can dramatically increase morbidity and mortality of otherwise sur-
vivable illnesses in the aged. This review also illustrates the conse-
quences of muscle atrophy in aging and illness and proposes steps to
combat these challenges.is is an open access article under the CC BY-NC-ND license (http://creativecommons.
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Muscle Structure and Classiﬁcation
Skeletal muscle comprises the ﬁbrillar proteins myosin (a thick
ﬁlament) and actin (a thin ﬁlament) that interact to cause muscle
contraction, a process requiring energy in the form of adenosine
triphosphate (ATP). Different muscle types have been classiﬁed ac-
cording to histochemical features, structural protein composition, and
major metabolic properties.5,6 Most commonly, skeletal muscles are
referred to as either “slow” or “fast” to reﬂect speeds of contraction, or
the shortening of myosin heavy chain (MHC) protein.6 The velocity of
this shortening is dependent on the MHC isoform present; “fast” ﬁber
isoforms MHCIIa and IIb demonstrate a higher shortening velocity
than their “slow” ﬁber MHCI counterparts.6,7 Classic histochemical
staining methods also classify muscle as type I (slow) and type II (fast)
based on the myosin ATPase enzyme forms revealed. Recently, these
types have been further distinguished based on histology (types I, IC,
IIC, IIAC, IIA, IIAB, and IIB).6Fig. 1. Glucose metabolism in fed, fasted and malnourished states. A, Glucose, lipids,
and amino acids from the diet circulate during the fed state for use or storage in body
organs. In the fasted state, glucose is released from the muscles, kidneys, and liver for
whole-body metabolism, along with lipids from adipose tissue and amino acids from
the muscle. B, When glucose stores have been depleted, amino acids are provided by
the muscles to support crucial bodily functions.Muscle Metabolism and Interorgan Crosstalk
Glucose regulation is central to energy balance both within muscle
ﬁbers and throughout the body. In the cytoplasm of most cells, glucose
undergoes glycolysis to produce the substrate for ATP generation.
Muscle ﬁbers are also characterized on the basis of the speed and
manner inwhich theymetabolize glucose. The terms “fast” and “slow”
can indicate the type of glucosemetabolism occurringwithin the ﬁber.
Slow muscles, which use aerobic metabolism, contain a high density
of capillaries and oxidative enzymes that allow a greater resistance to
fatigue.7 Fast muscles, which depend on anaerobic metabolism, or
glycolysis, can quickly generate ATP and therefore contract more
readily. Fast muscles also fatigue sooner than slow ﬁbers, as the
conversion of glucose to pyruvate generates less ATP than can be
generated by using the rest of central metabolism, ultimately gener-
ating CO2.
Muscle has the ability to store glucose in the form of glycogen,
which facilitates the rapid initiation of energy production for
contraction even when glucose is not readily available from the diet.
This unique capacity, shared also by the liver and kidneys, makes
skeletal muscle an important metabolic organ that helps all organs
have access to essential energy substrates during fasting. Furthermore,
the amino acids stored in muscle as protein can be broken down as a
last resort during times of starvation or extreme energy shortfalls.4
Patterns of glucose utilization throughout the body as a whole
reﬂect feeding status (Figure 1; Table 1). Based on a classic study of the
fed state (measurement within 3 hours of eating), researchers esti-
mated that 25% to 35% of an ingested carbohydrate load was quickly
extracted from circulation and stored by the liver.3 Of the remaining
glucose, approximately 40%was disposed in themuscle and 10% in the
kidney.3 The brain used 15% to 20% of post-meal glucose.3
In the fasted state (after 14 to 16 h without eating), the liver pro-
vides approximately 80% of glucose that is released into circulation.
About half of this glucose comes from the breakdown of stored
glycogen, and the rest from the metabolism of sources other than
carbohydrate or glycogen, including certain amino acids, through a
process known as gluconeogenesis.8 Interactions between muscle and
liver are largely responsible for regulating carbohydrate metabolism
and for achieving energy balance in normal fed and fasted states; the
kidneys play a role similar to that of the liver, but to a lesser extent.3,8
In addition, muscle tissue stores amino acids as protein, and adipose
tissue serves as a depot of glycerol and fatty acids. As needed, amino
acids and fatty acids can bemetabolized to form acetyl coenzyme A for
the tricarboxylic acid (TCA) cycle.As glycogen stores become depleted, increasingly more glucose is
produced by gluconeogenesis. Gluconeogenesis provides 70% of
glucose released into the body 24 hours after eating, and 90% by
48 hours.8 As fasting is prolonged, the kidneys contribute increasingly
higher amounts of glucose from gluconeogenesis.
Ultimately, amino acids stored in skeletal muscle are metabolized
when the need for gluconeogenesis substrate is greatest. Skeletal
muscle houses nearly 75% of all protein in the body and constitutes an
important contributor to gluconeogenesis in states of drastic deple-
tion. Maintenance of muscle protein content depends on the balance
between protein synthesis and degradation.5 Under normal condi-
tions, muscle protein mass gains during the fed state balance losses
during the fasted state.4 However, under severe metabolic stress
generated by serious illness or injury, muscle protein can become
Aging Illness
Malnutrition Risk
Table 1
Glucose Metabolism in Fasted and Fed States
Fed State Fasted State
Diet-sourced glucose (exogenous glucose) is absorbed from the intestine to
circulate in blood; glucose serves as an energy source in cells throughout the
body. Cytoplasmic glucose undergoes glycolysis, in turn producing ATP.
Little or no blood glucose from dietary sources; alternative energy sources are
needed for function of tissues body-wide.
Glucose is primarily taken up bymuscle and liver, where it can be used for energy
or stored as glycogen (Glycogen synthesis).
Glycogen stored in liver, kidney, andmuscle is broken down to provide glucose as
energy source (Glycogenolysis). Muscle uses glycogen-sourced glucose
internally; liver and kidney can supply glucose to circulation.
Gluconeogenic substrates are stored in various organs (eg, pyruvate in liver,
glycerol in fat, and amino acids in muscle).
Endogenous generation of glucose from noncarbohydrate carbon substrates, such
as pyruvate, lactate, glycerol, and glucogenic amino acids (Gluconeogenesis);
occurs primarily in the liver and muscle, and to a lesser extent in the kidney.
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limitations.
Skeletal muscle proteolysis can provide amino acid substrates for
glucose and glycogen formation, notably glutamine and alanine.
Alanine is released into circulation and reaches the liver, where it
serves as an excellent substrate for gluconeogenesis. Glutamine also
has a beneﬁcial role in this process: the carbon skeleton of glutamine
is a gluconeogenic precursor that can regulate gluconeogenesis
independently of the insulin/glucagon ratio. Therefore, glutamine
supplementation may also enhance glycogen synthesis and increase
muscle glycogen stores even when insulin levels are low or when
insulin resistance is present.9
In summary, dietary glucose is supplied by meals, and glucose is
stored as glycogen in liver, kidney, and muscle for metabolic energy
functions, as needed (Table 1). At times when glucose supplies are not
sufﬁcient to meet energy needs, breakdown of glycogen (glycogen-
olysis) occurs. When stored glucose products are no longer available,
energy is released by breakdown of substrates other than glucose. In
this review of muscle metabolism, we emphasize that amino acids
stored as protein in muscle can be broken down by way of gluco-
neogenesis, ultimately entering the TCA cycle for energy production.
Such breakdown occurs when energy demands are high, as with
stress-induced hypermetabolism of disease, or when supplies are low,
as in severe starvation or disease-associated loss of appetite. Such use
can become problematic in that it reduces skeletal muscle mass and
produces waste nitrogen, which requires further energy to sequester
and secrete. Prolonged reliance on these processes can accelerate
existing health problems and must be addressed by the health care
provider.Reduced
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Function
Skeletal muscle is remarkably plastic. It changes continuously in
response to calorie and nutrient intake, illness, and physical stress.
Changes in adult skeletal muscle also may occur as ﬁber-type
switching, which is inﬂuenced by changes in physical activity,
loading, nerve stimulation, or hormone and cytokine levels.7,10e12synthesis myogenesis degradation
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Fig. 2. Effects of aging and illness on muscle mass.Mechanisms of Muscle Growth and Strength Increase
Muscle adapts positively to demands placed on it, such as the
increased contractile activity associated with endurance training or
the increased loading attributable to strength training. This tremen-
dous plasticity is evident as muscle tissue accretion, speciﬁc changes
within muscle, and muscle tissue breakdown.1 Muscle growth, or
hypertrophy, occurs when protein synthesis within the muscles out-
paces protein degradation. This process can be positively regulated by
mammalian target of rapamycin (mTOR) signaling induced by insulin
after calorie ingestion, by hormones such as testosterone, and by
exercise.10Mechanisms of Muscle Loss in Aging, Inactivity, Sickness, and Frailty
This ability of skeletal muscle to change dynamically in response to
body conditions is also manifest as changes resulting from injury,
illness, or aging. When the metabolic demands placed on muscle
outweigh the protein synthesis that occurs from dietary intake and
after exercise, muscle mass is lost, metabolic storage products are
depleted, and muscle ﬁber balance changes.
Aging may lead to a loss of muscle mass resulting from both the
shrinking of muscle ﬁbers (atrophy) and the elimination of ﬁbers
altogether (Figure 2).6 This condition is known as primary sarcopenia,
the age-related loss of muscle mass and function. Although both ﬁber
types I and II lose mass, aging causes preferential atrophy of type II
ﬁbers; the net change is thus from type II to type I ﬁbers, or from fast
to slow muscle ﬁbers.6,13 Because fast muscle ﬁbers mobilize ATP and
create tension more readily than slow ﬁbers, this shift can leave older
adults without the energy to perform daily tasks.14 This shift to type I
Table 2
Major Molecular Pathways Inﬂuencing Muscle Accretion
Effector Mediator Major Pathway(s) Consequence
Mammalian target of
rapamycin (mTOR)
þInduced by BCAAs, HMB Interacts with protein translation
machinery to facilitate initiation and
elongation
mTOR stimulation by a number of
pathways increases protein synthesis
Insulinlike growth factor (IGF1) þStimulated by meal-induced insulin IGF1R/ PI3K/ AKT/ mTOR Reduced IGF1 from decreased eating
and/or exercise leads to reduced
protein synthesis and to muscle
wasting
þStimulated by exercise
Myostatin/Activin þProduced by skeletal muscle Activin receptors (ACTRIIA/B)/ Smad2/
3 eI mTOR
Myostatins negatively regulate protein
synthesis
eInhibited by Follistatin ACTRIIA/B/ FoxO/ UPS
Inﬂammatory cytokines (TNFa, IL-1) þUpregulated by illness, injury Cytokine receptors/ NFKB, p38, JAK,
Caspases, E3 ligases
Inﬂammation leads to apoptosis or
autophagy-mediated muscle cell loss
eInhibited by exercise FoxO transcription factors/ MAFBX;
MURF1/ UPS (ubiquitin-proteasome
system)
Vitamin D þLevels are increased by diet and
sunlight
Vitamin D receptor/ gene expression
or repression in myogenic cells
Vitamin D positively inﬂuences muscle
growth
AKT, protein kinase B; BCAA, branched-chain amino acid; FoxO, forkhead box protein O; HMB, b-Hydroxy b-Methylbutyrate; IGF1R, insulinlike growth factor 1 receptor; JAK,
janus kinase; MURF1, muscle RING-ﬁnger protein-1 p38, mitogen-activated protein kinase; PI3K, phosphatidylinositide 3-kinase; UPS, ubiquitin-proteasome system.
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oxidativemetabolism relative to the glycolytic metabolism that occurs
in type II fast ﬁbers. Exacerbating the problems caused by muscle
degradation in aging, it is possible that type I oxidative ﬁbers normally
experience higher protein turnover (i. protein synthesis and degra-
dation), are less able to grow in size, and have different responses to
insufﬁcient nutrient intake, although these ﬁber-type differences
remain poorly understood.7,15,16
Beyond aging, muscle wasting is associated with many pathological
states and chronic diseases, such asmalnutrition, cancer, chronic kidney
disease, chronic obstructive pulmonary disease, burns, muscular dys-
trophies, acquired immunodeﬁciency syndrome, sepsis, and immune
disorders, and forced immobilization and bed rest are devastating to
patientswho are already challenged by these factors (Figure 2).14,17Most
of these pathological conditions are associated with variable degrees of
local and/or systemic chronic inﬂammation,which plays a crucial role in
theonset ofmuscle atrophy. Loss ofmusclemass is frequently associated
with increased production of proinﬂammatory cytokines. Systemic
inﬂammation is associated with reduced rates of protein synthesis par-
alleled by enhanced protein breakdown, both accounting for the loss of
muscle mass. The effects exerted by proinﬂammatory cytokines on
musclemass are partiallymediated byactivating the transcription factor
nuclear factor kB (NF-kB).18 The transcriptional activity is regulated by
the phosphorylation and consequent degradation of the inhibitor Ik-Ba,
allowing the positive regulation of muscle RING-ﬁnger protein-1
(MuRF1) and other atrophy-related genes. Proinﬂammatory cytokines
act on muscle protein metabolism not only by activating catabolic
pathways, but also bydownregulating the anabolic pathways.19 Elevated
tumor necrosis factor-alpha (TNF-a) and interleukin-1 (IL-1) lead to in-
hibition of the Akt/mTOR signal transductionpathway and a subsequent
reduction in protein synthesis. The inﬂammatory process that takes
placeduring traumaor fractures is controlled andﬁnely regulated. In the
short term, it can facilitate complete and efﬁcient reconstruction of
muscle ﬁbers through the stimulation of myogenesis. However, chronic
inﬂammation can be deleterious, driving uncontrolled muscle atrophy
and affecting contraction ability. Balance between pro- and anti-
inﬂammatory cytokines is well known to be important in regulating
physiological muscle protein turnover and myogenesis, and evidence
suggesting that inﬂammation can impair force generation in muscles is
also growing.20,21
As inﬂammation accelerates muscle catabolism, resting energy
expenditure increases and amino acids are released from muscles to
serve as substrates for gluconeogenesis in liver and elsewhere in the
body (Table 2).22 The efﬁciency of energy production is low whenamino acids are used to generate energy, so muscle is at further risk
for breakdown to meet needs.23 In addition, the liver changes meta-
bolic priorities, using amino acids to produce acute phase reactant
proteins instead of normal proteins, such as serum albumin, and to
support gluconeogenesis. This process continues until the cause of
stress has subsided. Thus, when the dietary proteins supplied are
inadequate to meet needs, muscle protein is broken down to supply
amino acids throughout the body. This reaction releases waste nitro-
gen, which requires further energy to convert to urea, thereby exac-
erbating the problem of the energy shortfall.24
Complications Associated With Loss of Muscle
As aging and illness lead to muscle breakdown and atrophy,
reduced muscle mass leaves patients without a crucial reservoir of
amino acids and effector molecules, such as myokines, cytokines
released by muscle, to help the body combat illness, infection, and
wasting (Figure 3).23,25e27 Therefore, muscle atrophy is associated
with a wide range of harmful health effects that can be life changing,
especially for older people.28e36 The most relevant condition associ-
ated with the presence of sarcopenia in this population is a clinical
syndrome called frailty. The most accepted physiological framework
explaining frailty and its consequences was proposed by Walston and
Fried,37 who described a relationship between sarcopenia and energy
imbalance called the “frailty cycle.” This cycle affects multiple systems,
especially those susceptible to changes in hormones (mainly sexual
hormones, IGF-1, and insulin) and the progressive development of a
proinﬂammatory state.38e40 Additional biomarkers have recently
been identiﬁed for roles in frailty, such as those related to endothelial
dysfunction or micro RNAs central to the aging process.41,42 Frailty can
be deﬁned as an age-associated biological syndrome characterized by
a decreased biological reserve resulting from a decline in multiple
physiological systems that leaves the individual at risk for developing
poor outcomes (disability, death, and hospitalization) in the presence
of stressors.43,44 The prevalence of frailty in people older than 65 is
approximately 10%, increases with age, and is greater in women.45
Frailty is nowa recognized clinical medical syndrome that provides
a biological framework for understanding vulnerabilities resulting
from aging or chronic conditions.44,46 It is clinically important to
detect frailty in those at risk of developing disability. As aging pro-
gresses, frailty increases as the prognostic factor for death and inci-
dent disability.47,48 Frailty and its underlying sarcopenia have been
shown to predict risk of death, disability, and other adverse outcomes,
including muscle mass atrophy, metabolic deterioration, slowed
Fig. 4. Treatments for sarcopenia. It is currently recommended that patients at risk of
or suffering from sarcopenia consume a diet high in protein, engage in resistance
exercise, and take supplements of the leucine metabolite HMB.
Fig. 3. Complications of lean body mass (muscle) loss.
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illness.32,34,35 Frailty and theweakness that followsmuscle loss lead to
higher risk of falls, fractures,30 physical disability,29 need for institu-
tional care,29 reduced quality of life,36 and heightened mortality.29,33
Early identiﬁcation of frailty risk provides the opportunity to pro-
vide interventions and avoid or delay disability as well as enhance
recovery.
Loss of muscle associated with disease, injury, disuse, or aging
signiﬁcantly increases the cost of health care.34,49,50 Results of a recent
study showed that older adults (mean age=70 years) who were very
frail spent (Euro) 1917 more on total health costs in an interval of 3
months than did those who were not frail.51 In the United States, the
direct cost of cachexia/sarcopenia to health care was reported to be
1.5% of annual total health care expenses.50 Such costs arise from the
increased rate of hospitalization, incidence of complications, lengths
of stay, and likelihood of readmission.52,53 In the face of an aging
population, the importance of identifying, preventing, and treating
muscle loss cannot be overstated.
Detection and Treatment of Muscle Loss
Who Is at Risk of Muscle Atrophy, and How Do We Identify It?
Screening is crucial for predicting risk, and proper, timely inter-
vention can reduce or eliminate the ensuing muscle mass and meta-
bolic atrophy, substantially affecting morbidity, mortality, and cost.
Special attention should be paid to the main risk categories: people
who are malnourished or at risk of malnutrition for any reason33,54;
frail adults, especially the very old; people who become decondi-
tioned and lose muscle due to age- and disability-related physical
inactivity35; those with diseases or conditions with inﬂammatory
components, such as chronic heart failure,55 chronic or acute kidney
disease,56 cancer,57e59 severe infection and sepsis,60 insulin resis-
tance/diabetes,61 intensive care uniteacquired weakness,25 and
wound/surgical recovery.34
Reaching an accurate diagnosis of age- or disease-related muscle
atrophy is difﬁcult, and a number of criteria have been proposed but
have not yet assessed in the clinical setting.14 Nonetheless, speciﬁc
criteria and measures can be used to diagnose sarcopenia or
cachexia.13,27,62,63 Sarcopenia can be diagnosed when a patient has
muscle mass that is at least 2 SDs below the relevant population mean
and also presents with a low gait (walking) speed. In addition, lowmuscle strength and general physical performance may be taken into
consideration.14 Cachexia can be diagnosed when at least 5% of body
weight is lost within 12 months in the presence of underlying illness,
and 3 of the following criteria are also met: decreased muscle
strength, increased fatigue, anorexia, low fat-free mass index,
abnormal biochemistry, increased inﬂammatory markers C-reactive
protein (>5.0 mg/L) or IL-6 (>4.0 pg/mL), anemia (<12 g/dL), or low
serum albumin (<3.2 g/dL).
Recent research into themolecular adaptations associated with the
development of or that result from muscle atrophy and metabolic
depletion may lead to the identiﬁcation of biomarkers and, therefore,
improvements in early detection (Table 2). A variety of signaling
pathways known to positively inﬂuence muscle growth (bone
morphogenetic proteins, brain-derived neurotrophic factors, folli-
statin, and irisin), as well as those known to negatively regulate
muscle growth (transforming growth factor b, myostatin, activins, and
growth and differentiation factor-15) and factors associated with
muscle function and dysfunction (C-terminal agrin fragment and
skeletal muscle speciﬁc troponin T) may emerge as biomarkers for
muscle atrophy in aging and disease.64 To date, there is no universally
recognized biomarker for muscle atrophy, but recent research in the
ﬁeld suggests that the combination of several biomarkers may facili-
tate the adequate diagnosis of muscle atrophy. Identiﬁcation of such
biomarkers and their incorporation into validated testing instruments
should allow early identiﬁcation of muscle atrophy (improving prog-
nosis, and likely reducing cost to health care systems), but may also
provide exciting targets for the development of new medications.
Nutritional Strategies for Maintaining and Rebuilding Muscle
Treatment of patients at risk can prevent or delay onset of muscle
atrophy, or even target rebuilding of muscle when muscle atrophy is
already evident (Figure 4).65 As a ﬁrst step, treatment must provide
adequate energy so that muscle proteins and their constituent amino
acids are spared as an energy source. In addition, high protein intake is
vital to treatment of muscle atrophy or for delaying its onset.7,66e69 It
should be noted that the range of protein needs can vary widely from
patient to patient. Because muscle mass may decrease or remain the
same (based largely on how much protein synthesis outpaces protein
degradation), the most direct way to prevent muscle loss is to ensure
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supplements (ONS; 20% of total calories as protein) may be beneﬁ-
cial to such patients.70
By deﬁnition, the essential amino acids (EAAs) play a central role in
protein nutritional status. Some amino acids play roles that are
distinct from the traditional one of protein building blocks; many of
these have little or nothing to do with protein synthesis, and are thus
not included here. However, of central importance to the current
discussion are the branched-chain amino acids (BCAAs), especially
leucine.65,71,72 BCAAs promote protein synthesis in the muscles
through a number of pathways.66 In particular, they are now known to
have a key role in altering tissue response to a meal, the post-prandial
response, especially in muscle, where they signal a reduction in pro-
tein breakdown and an increase in protein synthesis, resulting in net
accretion of protein in muscle and helping to regulate blood amino
acid levels. However, aspects of this postprandial regulation are not as
robust in aged muscle, and muscle in hypercatabolic conditions, such
as cancer, is challenged and its normal system is overwhelmed. In
these cases, a substantial body of research suggests that signiﬁcantly
more of these amino acids are required in the diet to overcome
resistance to protein anabolism; very high doses, such as 10 to 15 g of
BCAAs, or 3 g or more of leucine per meal, have been studied to
combat muscle loss in the elderly,44 although this may be a result of
improved protein synthesis that does not lead to muscle mass
accretion.73e75
This resistance to the normal of BCAAs in muscle protein homeo-
stasis has prompted studies into leucine’s mechanism of action. These
have identiﬁed the leucine metabolite b-hydroxy b-methylbutyrate
(HMB) as a potent stimulator of protein synthesis as well as an in-
hibitor of protein breakdown in the extreme case of
cachexia.65,72,76e84 A growing body of evidence suggests HMB may
help slow, or even reverse, the muscle loss experienced in sarcopenia
and improve measures of muscle strength.44,65,72,76e84 However, di-
etary leucine does not provide a large amount of HMB: only a small
portion, as little as 5%, of catabolized leucine is metabolized into
HMB.85 Thus, although dietary leucine itself can lead to a modest
stimulation of protein synthesis by producing a small amount of HMB,
direct ingestion of HMBmore potently affects such signaling, resulting
in demonstrable muscle mass accretion.71,80 Indeed, a vast number of
studies have found that supplementation of HMB to the diet may
reverse some of the muscle loss seen in sarcopenia and in hyper-
catabolic disease.65,72,83,86,87 The overall treatment of muscle atrophy
should include dietary supplementation with HMB, although the
optimal dosage for each condition is still under investigation.68
In addition to dietary protein, EAAs/BCAAs including leucine, the
leucine metabolite HMB, a number of other dietary or supplemental
components have been explored for their ability to positively inﬂu-
ence muscle mass during sarcopenia. These include creatine mono-
hydrate, a variety of antioxidants, ornithine a-ketoglutarate, omega-3
fatty acids, ursolic acid, and nitrates.68,88e90 Given the length of this
list, its growing nature, and the difﬁculty many aged individuals
experience ingesting proper calories and nutrients, additional studies
will be needed to determine which components are most beneﬁcial to
maintaining muscle mass, as well as their optimal doses and admin-
istration routes both in isolation and in combination.
Physical Activity Is Also Key
Nutrition is important and can counteract metabolic alterations
induced during periods of signiﬁcant stress and inﬂammation; how-
ever, sufﬁcient exogenous provisions of protein and energy substrates
alone cannot completely eliminate or reverse the deteriorations
associated with aging or the deleterious impact inadequate control
and regulation of inﬂammation have on muscle.23,66,69 Protein syn-
thesis occurs in muscle ﬁbers following their contraction,91 andphysical activity has been shown to induce a number of anabolic
signaling pathways.92 Physical activity can likewise reduce degrada-
tion of muscle protein.93,94 Even more, a lack of physical activity in-
creases the resistance of muscle to anabolism, particularly the
synthesis of proteins from amino acids.95 An exercise component to
muscle atrophy treatment is therefore highly recommended, and ex-
ercise alsomay prevent the onset of sarcopenia later in life, possibly by
increasing the presence of type I ﬁbers that are less susceptible to
degradation during sarcopenia.7,25,66,89 Although aerobic and other
types of exercise are all preferable to a lack of physical activity,
resistance exercise in particular has been shown repeatedly to
improve rates of protein synthesis and reverse muscle loss.88,89,94 This
may be attributable to differential effects on muscle ﬁber types.7 It is
therefore recommended that patients with muscle atrophy or at risk
of developing muscle atrophy engage a regular exercise program
containing both aerobic and anaerobic components, and the impor-
tance of appropriate resistance training cannot be overstated.
Although this must be tailored to the individual’s current physical
status, it should also periodically be reviewed and increased to
maximize its impact.
Although resistance exercise and general physical activity are
important to the stimulation of protein synthesis from amino acids in
the diet, some aged and ill individuals experiencing extensive muscle
atrophy are likely to have difﬁculty engaging in physical activities
because of low energy and other medical complications. Nutrition and
some supplements can be used to bolster results of exercise, both
preventively and during sarcopenia. For example, bioactive substances
known as nutraceuticals that mimic the molecular effects of exercise
can induce signaling pathways that are thought to support or even
underlie exercise’s effects on health andmusclemass accretion. Found
in a variety of foods, including some common fruits, green tea, and
even red wine, these compounds can be isolated and added to
nutritional supplements used in the treatment of muscle atrophy.44
Summary and Conclusions
The classic physical functions of skeletal muscle are well known,
but skeletal muscle is increasingly recognized as a one of the key
regulators of energy and protein metabolism by way of metabolic
crosstalk between body organs. Skeletal muscle is the primary site for
glucose uptake and storage, and it is likewise a reservoir of amino
acids that sustain protein synthesis in all other body sites. When di-
etary glucose intake decreases or metabolic needs increase, stored
glucose is mobilized from liver, while energy is released from fat de-
pots. When these energy supplies are depleted, the muscle reservoir
of amino acids stores is tapped, and muscle proteins are broken down
to provide amino acids for gluconeogenesis, thereby supplying energy
to other parts of the body.
Undernutrition and resultant muscle loss (muscle atrophy), as
associated with aging and disease, can lead to adverse health and
economic consequences. Conditions and diseases that lower dietary
intake and increase nutrient needs are associated with catabolism of
skeletal muscle, which in turn limits availability of protein and energy
throughout the body. Loss of muscle mass, strength, and function has
adverse consequences: slowed wound healing and recovery from
illness, physical disability (due both to overall reduction of muscle
status), as well as selective losses in type I ﬁbers, which are essential
for balance recovery (and thus fall prevention), poorer quality of life,
and higher health care costs.
Nutrition and exercise are key to growth and maintenance of
muscle promoting overall health, well-being, and recovery from dis-
ease. A wealth of research underscores the importance of a few key
dietary components: protein (EAAs/BCAAs in particular), and the
leucine metabolite HMB. Others will very likely be added to this list as
our knowledge base grows. In addition, physical activity, especially
J.M. Argilés et al. / JAMDA 17 (2016) 789e796 795resistance strength training, is essential to the treatment of muscle
atrophy. Others will very likely be added to this list as our knowledge
base grows. Considerable evidence shows that ONS and enteral
feeding formulations can help maintain and rebuild muscle mass and
strength. Further studies are needed to show support for functional
outcomes, such as ability to perform activities of daily living and
maintain or restore independence.Acknowledgments
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